Patents by Inventor Silvia Rossi
Silvia Rossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240110926Abstract: The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1? and TNF-? cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.Type: ApplicationFiled: December 15, 2021Publication date: April 4, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Sonia BUDRONI, Simona RONDINI, Silvia ROSSI PACCANI
-
Patent number: 11801328Abstract: The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.Type: GrantFiled: July 28, 2017Date of Patent: October 31, 2023Assignee: UNIVERSITÁ DEGLI STUDI DI PAVIAInventors: Giuseppina Sandri, Maria Cristina Bonferoni, Silvia Rossi, Franca Ferrari
-
Publication number: 20230266317Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.Type: ApplicationFiled: September 9, 2020Publication date: August 24, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael CHAPLET, Nathalie NORAIS, Simona RONDINI, Silvia ROSSI PACCANI
-
Publication number: 20220221455Abstract: The present invention relates to the field of antigen binding proteins and the use of such antigen binding proteins in an assay. More particularly, it relates to antigen binding proteins which bind to an epitope of Protein E and antigen binding proteins which bind to an epitope of PilA. The present invention also relates to assays (particularly in vitro assays) for assessing binding to Protein E and/or PilA and the potency of vaccines containing Protein E and/or PilA. In particular the invention relates to in vitro relative potency assays used in the release of a vaccine to the public.Type: ApplicationFiled: April 16, 2020Publication date: July 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nathalie NORAIS, Silvia ROSSI PACCANI, Simona RONDINI
-
Publication number: 20210154300Abstract: The invention provides a composition for use as a delivery vehicle comprising at least one thermo-responsive polymer (polymer A) and at least one ion-sensitive polymer (polymer B) in a liquid formulation. Polymer A is preferably a polyoxyethylene-polyoxypropylene block copolymer or a cellulose derivative. Polymer B a polysaccharide. The composition can include an active substance for delivery or can be used as a delivery vehicle for a substance added at the time of administration such as mesenchymal stem cells.Type: ApplicationFiled: December 20, 2018Publication date: May 27, 2021Applicant: COSMO TECHNOLOGIES LTD.Inventors: Franca FERRARI, Cristina BONFERONI, Giuseppina SANDRI, Luigi Maria LONGO, Cristina MACELLONI, Silvia ROSSI
-
Publication number: 20210007993Abstract: The present invention provides an innovative combination of biomaterials, multifunctional polymers, able to structure themselves at the site of action. The innovative combination of biomaterials of the invention is formulated in a solid composition and can be used as a versatile delivery vehicle or carrier in many pharmaceutical fields. The solid composition comprising the combination of biomaterials of the invention is provided to target delivery for medical purposes in humans.Type: ApplicationFiled: December 20, 2018Publication date: January 14, 2021Applicant: COSMO TECHNOLOGIES LTD.Inventors: Luigi Maria LONGO, Cristina MACELLONI, Silvia ROSSI, Franca FERRARI
-
Publication number: 20200405841Abstract: The present invention relates to the field of immunogenic compositions and vaccines and the use of such compositions in medicine. More particularly, it relates to immunogenic fragments of UspA2 comprising an epitope and immunogenic compositions and vaccines comprising said fragments, for use in preventing or treating an infection, disease or condition caused by heterologous strain(s) of Moraxella catarrhalis. The invention further relates to immunogenic compositions and vaccines comprising an immunogenic fragment wherein said fragment comprises an epitope with cross-bactericidal activity.Type: ApplicationFiled: March 6, 2019Publication date: December 31, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nathalie Isabelle Devos, Vincent DEWAR, Philippe Vincent HERMAND, Silvia ROSSI PACCANI, Vincent WEYNANTS
-
Publication number: 20200230290Abstract: The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.Type: ApplicationFiled: July 28, 2017Publication date: July 23, 2020Applicant: UNIVERSITA' DEGLI STUDI DI PAVIAInventors: Giuseppina SANDRI, Maria Cristina BONFERONI, Silvia ROSSI, Franca FERRARI
-
Publication number: 20190290748Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.Type: ApplicationFiled: March 25, 2019Publication date: September 26, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Marco SORIANI, Maria SCARSELLI, Nathalie NORAIS, Danilo GOMES MORIEL, Silvia ROSSI PACCANI
-
Patent number: 10279026Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.Type: GrantFiled: April 24, 2013Date of Patent: May 7, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Marco Soriani, Maria Scarselli, Nathalie Norais, Danilo Gomes Moriel, Silvia Rossi Paccani
-
Publication number: 20150272919Abstract: Pharmaceutical compositions useful in the treatment of sexual and urogenital dysfunctions such as dyspareunia, vulvodynia, vaginismus, vestibulitis and anal fistulas.Type: ApplicationFiled: September 19, 2013Publication date: October 1, 2015Applicant: Dipharma Francis S.r.l.Inventors: Franca Ferrari, Silvia Rossi, Maria Cristina Bonferoni, Giuseppina Sandri, Carla Caramella, Pietro Allegrini
-
Publication number: 20150202279Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.Type: ApplicationFiled: April 24, 2013Publication date: July 23, 2015Inventors: Marco Soriani, Maria Scarselli, Nathalie Norais, Danilo Gomes Moriel, Silvia Rossi Paccani
-
Patent number: 8633169Abstract: The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and high resistance to physiological removal mechanisms.Type: GrantFiled: September 3, 2008Date of Patent: January 21, 2014Assignee: Fidia Farmaceutici S.p.A.Inventors: Carla Marcella Caramella, Silvia Rossi, Giuseppina Sandri, Giovanni Gennari
-
Publication number: 20120088726Abstract: Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.Type: ApplicationFiled: October 19, 2011Publication date: April 12, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Bottoni, Paola Maffei, Annalisa Sforzini, Mascia Federici, Carla Caramella, Silvia Rossi, Giuseppe Claudio Viscomi
-
Publication number: 20100249156Abstract: The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and high resistance to physiological removal mechanisms.Type: ApplicationFiled: September 3, 2008Publication date: September 30, 2010Inventors: Carla Marcella Caramella, Silvia Rossi, Giuseppina Sandri, Giovanni Gennari
-
Publication number: 20090081133Abstract: Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.Type: ApplicationFiled: June 1, 2006Publication date: March 26, 2009Inventors: Giuseppe Bottoni, Paola Maffei, Annalisa Sforzini, Mascia Federici, Carla Caramella, Silvia Rossi, Giuseppe Claudio Viscomi